The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...

The global Progressive Pulmonary Fibrosis (PPF) Treatment Market is set to achieve a valuation of USD 3.72 million in 2023, ...

In cases of pulmonary fibrosis attributable to interstitial lung disease, whether the aetiology is known or unknown, the ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. | ...

AN INSIGHTFUL session on the future of lung transplantation presented at this year’s European Respiratory Society (ERS) ...

A higher abundance of monocyte-derived alveolar macrophages significantly correlated with worse lung fibrosis in RPRA ...

IPF is a chronic, progressive lung disease marked by lung tissue thickening and scarring, leading to reduced lung function. It is a specific type of interstitial lung disease, which includes various ...

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and (BMC) have announced a new collaboration with the global biopharma company GSK to advance innovative research ...

When you can't breathe, the world stops,' a retired HPD officer said of his near-death battle with COVID-19. Fortunately, his world didn't stop; he discovered a new sense of purpose as a health ...

Gene-editing therapies—techniques that modify DNA to treat or prevent disease—have the potential to transform the field of ...

Emily Pink, 21, has cystic fibrosis, a rare genetic disorder that causes a build-up of sticky mucus in her lungs and ...

Anti-fibrotic therapies, like Ofev and Genentech's Esbriet (pirfenidone), work by slowing the rate of fibrosis and are ...